Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0902 Phase 1a SAD in Healthy Males
NCT06563713Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSP-0902 in oligozoospermia and asthenozoospermia (6 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Number of treatment-related adverse events at 28 days. Started Jul 2024; status: completed.
02
Drugs
STSP-0902
03
Conditions
oligozoospermiaasthenozoospermia
Beyond the preview
Go deeper on NCT06563713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563713.